IndEx-2: Deciphering the impact of antigen density on tumour targeting therapeutics

Assessing the impact of antigen density on therapeutic efficacy and safety rely on cell lines with varying antigen expression levels. However, establishing a large panel of such cell lines is logistically and methodologically difficult due to licensing costs, limited availability, and uncertainty around specific antigen expression levels. Discover RoukenBio's comprehensive approach for evaluating the influence of antigen expression levels on the efficacy and safety of therapeutic modalities, such as immune cell engagers, CAR-based cell therapies, conventional monoclonal antibodies and ADCs.